CLBS 14 - Caladrius Biosciences

Drug Profile

CLBS 14 - Caladrius Biosciences

Alternative Names: CD34+ cell therapy; CLBS14 - Caladrius Biosciences

Latest Information Update: 09 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Caladrius Biosciences
  • Class Cardiovascular therapies; Cell therapies
  • Mechanism of Action CD34-antigen-stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cardiovascular disorders

Most Recent Events

  • 02 Oct 2017 Caladrius Biosciences has patent protection for CLBS 14 in USA
  • 02 Oct 2017 Preclinical trials in Cardiovascular disorders in USA (Infusion) before October 2017
  • 02 Oct 2017 Caladrius Biosciences plans a phase II trial for Coronary microvascular dysfunction in USA in early 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top